- Home
- AMTB vs RCUS Comparison
AMTB vs RCUS Comparison
Compare AMTB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- RCUS
- Stock Information
- Founded
- AMTB 1979
- RCUS 2015
- Country
- AMTB United States
- RCUS United States
- Employees
- AMTB N/A
- RCUS N/A
- Industry
- AMTB Major Banks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- RCUS Health Care
- Exchange
- AMTB Nasdaq
- RCUS Nasdaq
- Market Cap
- AMTB 758.4M
- RCUS 727.1M
- IPO Year
- AMTB N/A
- RCUS 2018
- Fundamental
- Price
- AMTB $17.70
- RCUS $8.28
- Analyst Decision
- AMTB Hold
- RCUS Buy
- Analyst Count
- AMTB 6
- RCUS 11
- Target Price
- AMTB $24.75
- RCUS $25.33
- AVG Volume (30 Days)
- AMTB 210.4K
- RCUS 1.2M
- Earning Date
- AMTB 04-23-2025
- RCUS 05-06-2025
- Dividend Yield
- AMTB 2.06%
- RCUS N/A
- EPS Growth
- AMTB N/A
- RCUS N/A
- EPS
- AMTB N/A
- RCUS N/A
- Revenue
- AMTB $280,716,000.00
- RCUS $141,000,000.00
- Revenue This Year
- AMTB $60.43
- RCUS N/A
- Revenue Next Year
- AMTB $11.66
- RCUS $25.77
- P/E Ratio
- AMTB N/A
- RCUS N/A
- Revenue Growth
- AMTB N/A
- RCUS N/A
- 52 Week Low
- AMTB $16.21
- RCUS $6.50
- 52 Week High
- AMTB $27.00
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- AMTB 44.60
- RCUS 48.63
- Support Level
- AMTB $16.44
- RCUS $7.06
- Resistance Level
- AMTB $17.77
- RCUS $9.35
- Average True Range (ATR)
- AMTB 0.70
- RCUS 0.55
- MACD
- AMTB 0.15
- RCUS 0.06
- Stochastic Oscillator
- AMTB 38.30
- RCUS 53.28
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.